EyePoint, Inc.
Close on Oct 19, 2026
- Market cap
- $38.08K
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | Before market open | $500.00K | $-1.09 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | Before market open | $700.00K | $-0.99 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 4, 2026 | Before market open | $600.00K | $-0.81 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | Before market open | $1.00M | $-0.85 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | Before market open | $5.30M | $-0.85 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | Before market open | $24.50M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 5, 2025 | Before market open | $11.60M | $-0.64 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | $10.50M | $-0.54 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 7, 2024 | Before market open | – | – | – |
Press releases
Announcements EyePoint filed with the SEC
EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU TM in Wet AMD
Other events · EX-99.1 to Form 8-K
LUCIA Phase 3 Clinical Trial DURAVYU in Wet AMD Topline Results | October 2026 Exhibit 99.2
Other events · EX-99.2 to Form 8-K
LUGANO Phase 3 Clinical Trial DURAVYU in Wet AMD Expanded Results & Analyses | September 2026 Exhibit 99.1
Other events · EX-99.1 to Form 8-K
EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU TM 2.7mg in Wet AMD
Other events · EX-99.1 to Form 8-K
LUGANO Phase 3 Clinical Trial Topline Results DURAVYU in Wet AMD August 17, 2026 Exhibit 99.2
Other events · EX-99.2 to Form 8-K
EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments
Results of operations · EX-99.1 to Form 8-K
Investor Presentation August 2026 Exhibit 99.2
Results of operations · EX-99.2 to Form 8-K
EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU for Treatment of Diabetic Macular Edema (DME)
Other events · EX-99.1 to Form 8-K
EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments
Results of operations · EX-99.1 to Form 8-K
Investor Presentation April 2026 Exhibit 99.1
Other events · EX-99.1 to Form 8-K
EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments
Results of operations · EX-99.1 to Form 8-K
EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU for the Treatment of Diabetic Macular Edema
Other events · EX-99.1 to Form 8-K
Investor Presentation March 2026 Exhibit 99.2
Other events · EX-99.2 to Form 8-K
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026
Results of operations · EX-99.1 to Form 8-K
EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring
Other events · EX-99.1 to Form 8-K
EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments
Results of operations · EX-99.1 to Form 8-K
EyePoint Announces Proposed Public Offering of Common Stock
Material agreement · Other events · EX-99.1 to Form 8-K
EyePoint Announces Pricing of Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU in Diabetic Macular Edema
Results of operations · Other events · EX-99.1 to Form 8-K
EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments
Results of operations · EX-99.1 to Form 8-K
EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration
Other events · EX-99.1 to Form 8-K/A
Investor Presentation July 2025 ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Exhibit 99.2
Other events · EX-99.2 to Form 8-K/A
EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration
Other events · EX-99.1 to Form 8-K
Investor Presentation July 2025 ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Exhibit 99.2
Other events · EX-99.2 to Form 8-K
Investor Presentation May 2025 ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Exhibit 99.2
Other events · EX-99.2 to Form 8-K
EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments
Results of operations · Other events · EX-99.1 to Form 8-K
Investor Presentation May 2025 ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Exhibit 99.2
Results of operations · Other events · EX-99.2 to Form 8-K
EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments
Results of operations · EX-99.1 to Form 8-K
Investor Presentation February 2025 ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Exhibit 99.2
Other events · EX-99.2 to Form 8-K
J.P. Morgan Healthcare Conference Presentation January 14, 2025 Jay Duker, M.D. President and CEO ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Exhibit 99.1
Results of operations · Other events · EX-99.1 to Form 8-K
EyePoint Provides Company Update and Anticipated Development Milestones for 2025
Results of operations · Other events · EX-99.2 to Form 8-K
EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors
Executive or director change · Other events · EX-99.1 to Form 8-K
EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments
Results of operations · EX-99.1 to Form 8-K
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
Material agreement · Other events · EX-99.1 to Form 8-K